PGx Testing for Oncology
TEST DESCRIPTION
Fulgent Oncology's Pharmacogenetic (PGx) tests give clinicians the tools to better understand how their patients will respond to certain medications.
With PGx testing, it's possible to tailor medication plans to a patient's specific genetic makeup. This can lead to reduced medical costs for patients and providers, safer medication plans, and greater drug efficacy. The PGx Oncology Panel includes genes associated with drug metabolism with high-level evidence and clinically actionable guidelines.
The PGx Oncology panel results associated with over 15 different oncology medications, including:
- 5-fluorouracil (5-FU)
- Capecitabine
- Tamoxifen
- Method: NGS
- Turnaround Time: 10-14 days
PGx Oncology
The PGx Oncology Panel includes only genes associated with actionable and informative oncology drug metabolism that are included in either the FDA's pharmacogenetic associations for which the data support therapeutic management recommendations list or other PGx clinical implementation guideline (CPIC).
PGx testing includes genes associated with various oncology medications, including antineoplastic agents, estrogen modulators, hypoxia-inducible factor inhibitors, detoxifying agents, and antibody-drug conjugates.
Genes: ABCB1, CYP2C9, CYP2C19, CYPD26, DPYD, ERCC1, G6PD, GSTP1, MTHFR, NQO1, NUDT15, TPMT, UGT1A1, UGT1A4, XRCC1 (15 genes)
FOR PGx TESTING
How It Works
Collect the sample
Sample collection kits are available upon request.
Place your order
Download and fill out our paper requisition.
Ship the sample to Fulgent
Send specimen and completed requisition to Fulgent Oncology.
Receive your report
All reports will be available within 10-14 business days of receipt of sample.
DPYD Variants
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has established guidelines for genotypes identified in the DPYD gene and dosing recommendations for fluorouracil and capecitabine. Fulgent Oncology's PGx Oncology panels assess specific DPYD variants (*1, *2A, *13, [c.1129-5923C>G, c.1236G>A (HapB3)], c.557A>G, c.868A>G, c.2279C>T, c.295_298delTCAT (*7), c.703C>T (*8), c.1314T>G, c.1774C>T, c.2639G>T).
*The FDA now recommends DPYD testing before administering certain chemotherapy drugs.
Important
The FDA has adopted a black box warning for capecitabine (Xeloda) requiring PGx testing for DPYD.
Why Use PGx Testing?
Research shows that over 90 percent of people carry at least one actionable or informative PGx variant and 65 percent of people are exposed to at least one PGx relevant drug. With PGx testing, you can learn about potential adverse reactions before an individual ever takes a drug, reducing the risk of "trial-and-error" prescribing.
References: PMID: 24253661, PMID: 22739144
Test Limitations
All sequencing technologies have limitations. Positive results do not imply that there are no other contributors, genetic or otherwise, to this individual's phenotype, and negative results do not rule out a genetic cause for the indication for testing. Annotations for FDA, PharmGKB, and CPIC guidelines are updated regularly. Official gene names change over time. Fulgent uses the most up to date gene names based on HUGO Gene Nomenclature Committee (https://www.genenames.org) recommendations. This assay is designed and validated for detection of germline variants only. It is not designed or validated for the detection of low-level mosaicism or somatic mutations. This assay will not detect certain types of genomic aberrations such as translocations, inversions, or repeat expansions (eg. trinucleotide or hexanucleotide repeat expansion). Analysis and reporting is limited to the diplotypes/markers explicitly listed on this report. This test cannot rule out the possibility that the tested individual has a rare or uncharacterized phenotype for genes on this panel.
Ready to learn more?
Connect with our experts to learn more about how we can help.